Biotech Series C Investors & VC Firms
600 firms in this list, with a median first check of $1M. 112 of them lead rounds. Generated from verified public data and updated continuously.
Healthcare Venture Partners, Llc
CharlestonSeries B–Late Stage
3 people
Hotung Investment Holdings Ltd.
SingaporeSeries A–Late Stage$300K – $1.5M
Invest Northern Ireland
BelfastSeed–Late Stage
Colt Ventures
DallasSeed–Growth$15M
3 people
Hillhouse Capital
ChangyangSeed–Series C$2.9M – $220M
Leaps by Bayer
LeverkusenSeed–Growth
7 people
Darwin Venture Management
TaipeiSeed–Late Stage$1M – $76M
Elmirate Capital
DubaiSeed–Late Stage$15M – $150M
Fulcrum Financial Partners
Raleigh-DurhamPre-Seed–Late Stage
3 people
IAG Capital Partners
CharlestonSeed–Late Stage
3 people
Innovation Engine
TokyoPre-Seed–Late Stage
3 people
IRDI SORIDEC Gestion
ToulouseSeed–Late Stage$216K – $16.2M
Red Capital
TokyoPre-Seed–Growth
3 people
Strategic Investment Partners Inc.
TokyoPre-Seed–Growth
2 people
Cathay Health
San FranciscoSeed–Late Stage
1 person
Syngenta Group Ventures
DurhamSeed–Growth$500K – $5M
5 people
Schouten Investments
AmsterdamSeries B–Late Stage
2 people
KSP, Inc.
KawasakiPre-Seed–Growth
1 person
SBI Investment
TokyoPre-Seed–Growth$2M – $227M
1 person
Shinsei Capital Partners
TokyoPre-Seed–Late Stage
Aurum Ventures MKI
Ramat GanSeed–Late Stage
8 people
Trans-Pacific Technology Fund
TaipeiSeed–Late Stage
8 people
Ambix Venture Management, Llc
Mountain ViewPre-Seed–Late Stage
2 people
Bridford Investments (Bridford Group)
LondonPre-Seed–Growth
2 people
Related lists
Series C Investors & VC Firms (2751)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Biotech Series A Investors & VC Firms (1596)Biotech Investors & VC Firms in United States (1039)Series C Investors & VC Firms in United States (946)Biotech Series B Investors & VC Firms (900)Series C Investors & VC Firms in Global (896)Biotech Pre-Seed Investors & VC Firms (896)Healthtech Series C Investors & VC Firms (771)
Data sourced from public filings and firms' own websites — see our methodology.











